Jump to content

Dopamine receptor D4

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Pengortm (talk | contribs) at 16:09, 30 June 2020 (Undid revision 965179905 by Mleonard85032 (talk) removing unsourced insertion). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

DRD4
Identifiers
AliasesDRD4, D4DR, dopamine receptor D4
External IDsOMIM: 126452; MGI: 94926; HomoloGene: 20215; GeneCards: DRD4; OMA:DRD4 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1815

13491

Ensembl

ENSG00000069696
ENSG00000276825

ENSMUSG00000025496

UniProt

P21917

P51436

RefSeq (mRNA)

NM_000797

NM_007878

RefSeq (protein)

NP_000788

NP_031904

Location (UCSC)Chr 11: 0.64 – 0.64 MbChr 7: 140.87 – 140.88 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The dopamine receptor D4 is a dopamine D2-like G protein-coupled receptor encoded by the DRD4 gene on chromosome 11 at 11p15.5.[5]

The structure of DRD4 was recently reported in complex with the antipsychotic drug nemonapride.[6]

As with other dopamine receptor subtypes, the D4 receptor is activated by the neurotransmitter dopamine. It is linked to many neurological and psychiatric conditions[7] including schizophrenia and bipolar disorder,[8] ADHD,[9][10] addictive behaviors,[11] Parkinson's disease,[12] and eating disorders such as anorexia nervosa.[13] A weak association has been drawn between DRD4 and borderline personality disorder.

It is also a target for drugs which treat schizophrenia and Parkinson's disease.[14] The D4 receptor is considered to be D2-like in which the activated receptor inhibits the enzyme adenylate cyclase, thereby reducing the intracellular concentration of the second messenger cyclic AMP.[15]

Genetics

The human protein is coded by the DRD4 on chromosome 11 located in 11p15.5.[16]

There are slight variations (mutations/polymorphisms) in the human gene:

Mutations in this gene have been associated with various behavioral phenotypes, including autonomic nervous system dysfunction, attention deficit/hyperactivity disorder,[19] schizophrenia[20] and the personality trait of novelty seeking.[21]

48-base pair VNTR

The 48-base pair variable number tandem repeat (VNTR) in exon 3 range from 2 to 11 repeats.[16] Dopamine is more potent at the D4 receptor with 2 allelic repeat or 7 allelic repeats than the variant with 4 allelic repeats.[22]

DRD4-7R, the 7-repeat (7R) variant of DRD4 (DRD4 7-repeat polymorphism), has been linked to a susceptibility for developing ADHD in several meta-analyses and other psychological traits and disorders.[23][24] Adults and children with the DRD4 7-repeat polymorphism show variations in auditory-evoked gamma oscillations, which may be related to attention processing.[25][26]

The frequency of the alleles varies greatly between populations, e.g., the 7-repeat version has high incidence in America and low in Asia.[27] "Long" versions of polymorphisms are the alleles with 6 to 10 repeats. 7R appears to react less strongly to dopamine molecules.[28]

The 48-base pair VNTR has been the subject of much speculation about its evolution and role in human behaviors cross-culturally. The 7R allele appears to have been selected for about 40,000 years ago.[27] In 1999 Chen and colleagues[29] observed that populations who migrated farther in the past 30,000 to 1,000 years ago had a higher frequency of 7R/long alleles. They also showed that nomadic populations had higher frequencies of 7R alleles than sedentary ones. More recently it was observed that the health status of nomadic Ariaal men was higher if they had 7R alleles. However, in recently sedentary (non-nomadic) Ariaal those with 7R alleles seemed to have slightly deteriorated health.[30]

Novelty seeking

Despite early findings of an association between the DRD4 48bp VNTR and novelty seeking (a normal characteristic of exploratory and excitable people),[31][32] a 2008 meta-analysis compared 36 published studies of novelty seeking and the polymorphism and found no effect. Results are consistent with novelty-seeking behavior being a complex trait associated with many genes, and the variance attributable to DRD4 by itself being very small. The meta-analysis of 11 studies did find that another polymorphism in the gene, the -521C/T, showed an association with novelty seeking.[21] While human results are not strong, research in animals has suggested stronger associations [33][34][35][36][37][38] and new evidence suggests that human encroachment may exert selection pressure in favor of DRD4 variants associated with novelty seeking.[39][clarification needed]

Cognition

Several studies have shown that agonists that activate the D4 receptor increase working memory performance and fear acquisition in monkeys and rodents according to a U-shaped dose response curve.[40][41][42] However, antagonists of the D4 receptor reverse stress-induced or drug-induced working memory deficits.[43][44] Gamma oscillations, which may be correlated with cognitive processing, can be increased by D4R agonists, but are not significantly reduced by D4R antagonists.[45][46][47]

Cognitive development

Several studies have suggested that parenting may affect the cognitive development of children with the 7-repeat allele of DRD4.[39] Parenting that has maternal sensitivity, mindfulness, and autonomy–support at 15 months was found to alter children's executive functions at 18 to 20 months.[39] Children with poorer quality parenting were more impulsive and sensation seeking than those with higher quality parenting.[39] Higher quality parenting was associated with better executive control in 4-year-olds.[39]

Ligands

Chemical structures of representative D4-preferring ligands.

Agonists

  • WAY-100635: potent full agonist, with 5-HT1A antagonistic component[48]
  • A-412,997: full agonist, > 100-fold selective over a panel of seventy different receptors and ion channels[49]
  • ABT-724 - developed for treatment of erectile dysfunction[50]
  • ABT-670 - better oral bioavailability than ABT-724[51]
  • FAUC 316: partial agonist, > 8600-fold selective over other dopamine receptor subtypes[52]
  • FAUC 299: partial agonist[52]
  • F-15063: antipsychotic with partial D4 agonism
  • (E)-1-aryl-3-(4-pyridinepiperazin-1-yl)propanone oximes[53]
  • PIP3EA: partial agonist[54]
  • Flibanserin - partial agonist
  • PD-168,077 - D4 selective but also binds to α1A, α2C and 5HT1A
  • CP-226,269 - D4 selective but also binds to D2, D3, α2A, α2C and 5HT1A
  • Ro10-5824 – partial agonist
  • Roxindole – D4 selective but also D2 and D3 autoreceptor agonist, 5HT1A receptor agonist, serotonin reuptake inhibitor)
  • Apomorphine – D4 selective but also D2 and D3 agonist, α-adrenergic and serotonergic weak antagonist

Antagonists

Inverse agonists

See also

References

  1. ^ a b c ENSG00000276825 GRCh38: Ensembl release 89: ENSG00000069696, ENSG00000276825 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025496 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (April 1991). "Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine". Nature. 350 (6319): 610–4. Bibcode:1991Natur.350..610V. doi:10.1038/350610a0. PMID 1840645.
  6. ^ Wang S, Wacker D, Levit A, Che T, Betz RM, McCorvy JD, Venkatakrishnan AJ, Huang XP, Dror RO, Shoichet BK, Roth BL (October 2017). "D4 dopamine receptor high-resolution structures enable the discovery of selective agonists". Science. 358 (6361): 381–386. Bibcode:2017Sci...358..381W. doi:10.1126/science.aan5468. PMC 5856174. PMID 29051383.
  7. ^ Ptácek R, Kuzelová H, Stefano GB (September 2011). "Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders". Medical Science Monitor. 17 (9): RA215–20. doi:10.12659/MSM.881925. PMC 3560519. PMID 21873960.
  8. ^ Domschke K (July 2013). "Clinical and molecular genetics of psychotic depression". Schizophrenia Bulletin. 39 (4): 766–75. doi:10.1093/schbul/sbt040. PMC 3686457. PMID 23512949.
  9. ^ LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL (May 1996). "Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder". Molecular Psychiatry. 1 (2): 121–4. PMID 9118321.
  10. ^ Smalley SL, Bailey JN, Palmer CG, Cantwell DP, McGough JJ, Del'Homme MA, Asarnow JR, Woodward JA, Ramsey C, Nelson SF (September 1998). "Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder". Molecular Psychiatry. 3 (5): 427–30. doi:10.1038/sj.mp.4000457. PMID 9774776.
  11. ^ McGeary J (September 2009). "The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review". Pharmacology Biochemistry and Behavior. 93 (3): 222–9. doi:10.1016/j.pbb.2009.03.010. PMC 2706302. PMID 19336242.
  12. ^ Cormier F, Muellner J, Corvol JC (April 2013). "Genetics of impulse control disorders in Parkinson's disease". Journal of Neural Transmission. 120 (4): 665–71. doi:10.1007/s00702-012-0934-4. PMID 23232665.
  13. ^ Rask-Andersen M, Olszewski PK, Levine AS, Schiöth HB (March 2010). "Molecular mechanisms underlying anorexia nervosa: focus on human gene association studies and systems controlling food intake". Brain Research Reviews. 62 (2): 147–64. doi:10.1016/j.brainresrev.2009.10.007. PMID 19931559.
  14. ^ Ptáček R, Kuželová H, Stefano GB, Raboch J, Kream RM (April 2013). "Targeted D4 dopamine receptors: implications for drug discovery and therapeutic development". Current Drug Targets. 14 (4): 507–12. doi:10.2174/1389450111314040012. PMID 23469923.
  15. ^ Neve KA, Seamans JK, Trantham-Davidson H (August 2004). "Dopamine receptor signaling". Journal of Receptor and Signal Transduction Research. 24 (3): 165–205. CiteSeerX 10.1.1.465.5011. doi:10.1081/RRS-200029981. PMID 15521361.
  16. ^ a b Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (July 1992). "Multiple dopamine D4 receptor variants in the human population". Nature. 358 (6382): 149–52. Bibcode:1992Natur.358..149T. doi:10.1038/358149a0. PMID 1319557.
  17. ^ Catalano M, Nobile M, Novelli E, Nöthen MM, Smeraldi E (October 1993). "Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients". Biological Psychiatry. 34 (7): 459–64. doi:10.1016/0006-3223(93)90236-7. PMID 8268330.
  18. ^ Rondou P, Haegeman G, Van Craenenbroeck K (June 2010). "The dopamine D4 receptor: biochemical and signalling properties". Cellular and Molecular Life Sciences. 67 (12): 1971–86. doi:10.1007/s00018-010-0293-y. PMID 20165900.
  19. ^ Thapar A, Langley K, Owen MJ, O'Donovan MC (December 2007). "Advances in genetic findings on attention deficit hyperactivity disorder". Psychological Medicine. 37 (12): 1681–92. doi:10.1017/S0033291707000773. PMID 17506925.
  20. ^ Gene Overview of All Published Schizophrenia-Association Studies for DRD4 Archived 21 February 2009 at the Wayback Machine – SzGene database at Schizophrenia Research Forum.
  21. ^ a b Munafò MR, Yalcin B, Willis-Owen SA, Flint J (January 2008). "Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data". Biological Psychiatry. 63 (2): 197–206. doi:10.1016/j.biopsych.2007.04.006. PMID 17574217.
  22. ^ Wedemeyer C, Goutman JD, Avale ME, Franchini LF, Rubinstein M, Calvo DJ (May 2007). "Functional activation by central monoamines of human dopamine D(4) receptor polymorphic variants coupled to GIRK channels in Xenopus oocytes". European Journal of Pharmacology. 562 (3): 165–73. doi:10.1016/j.ejphar.2007.01.055. PMID 17350612.
  23. ^ Wu J, Xiao H, Sun H, Zou L, Zhu LQ (June 2012). "Role of dopamine receptors in ADHD: a systematic meta-analysis". Molecular Neurobiology. 45 (3): 605–20. doi:10.1007/s12035-012-8278-5. PMID 22610946.
  24. ^ Faraone SV, Doyle AE, Mick E, Biederman J (July 2001). "Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder". The American Journal of Psychiatry. 158 (7): 1052–7. doi:10.1176/appi.ajp.158.7.1052. PMID 11431226.
  25. ^ Yordanova J, Banaschewski T, Kolev V, Woerner W, Rothenberger A (June 2001). "Abnormal early stages of task stimulus processing in children with attention-deficit hyperactivity disorder--evidence from event-related gamma oscillations". Clinical Neurophysiology. 112 (6): 1096–108. doi:10.1016/s1388-2457(01)00524-7. PMID 11377270.
  26. ^ Demiralp T, Herrmann CS, Erdal ME, Ergenoglu T, Keskin YH, Ergen M, Beydagi H (May 2007). "DRD4 and DAT1 polymorphisms modulate human gamma band responses". Cerebral Cortex. 17 (5): 1007–19. doi:10.1093/cercor/bhl011. PMID 16751296.
  27. ^ a b Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, Ryder OA, Spence MA, Swanson JM, Moyzis RK (May 2004). "The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus". American Journal of Human Genetics. 74 (5): 931–44. doi:10.1086/420854. PMC 1181986. PMID 15077199.
  28. ^ Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH (September 1995). "Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants". Journal of Neurochemistry. 65 (3): 1157–65. doi:10.1046/j.1471-4159.1995.65031157.x. PMID 7643093.
  29. ^ Chen CS, Burton M, Greenberger E, Dmitrieva J (1999). "Population Migration and the Variation of Dopamine D4 Receptor (DRD4) Allele Frequencies Around the Globe". Evolution and Human Behavior. 20 (5): 309–24. doi:10.1016/S1090-5138(99)00015-X.
  30. ^ Eisenberg DT, Campbell B, Gray PB, Sorenson MD (June 2008). "Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya". BMC Evolutionary Biology. 8: 173. doi:10.1186/1471-2148-8-173. PMC 2440754. PMID 18544160.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  31. ^ Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH (January 1996). "Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking". Nature Genetics. 12 (1): 78–80. doi:10.1038/ng0196-78. PMID 8528256.
  32. ^ Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH (January 1996). "Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking". Nature Genetics. 12 (1): 81–4. doi:10.1038/ng0196-81. PMID 8528258.
  33. ^ Fidler AE, van Oers K, Drent PJ, Kuhn S, Mueller JC, Kempenaers B (July 2007). "Drd4 gene polymorphisms are associated with personality variation in a passerine bird". Proceedings: Biological Sciences. 274 (1619): 1685–91. doi:10.1098/rspb.2007.0337. PMC 1914334. PMID 17472912.
  34. ^ Mueller JC, Edelaar P, Carrete M, Serrano D, Potti J, Blas J, Dingemanse NJ, Kempenaers B, Tella JL (June 2014). "Behaviour-related DRD4 polymorphisms in invasive bird populations". Molecular Ecology. 23 (11): 2876–85. doi:10.1111/mec.12763. hdl:10261/101638. PMID 24750181.
  35. ^ Ninomiya S, Anjiki A, Nishide Y, Mori M, Deguchi Y, Satoh T (July 2013). "Polymorphisms of the Dopamine D4 Receptor Gene in Stabled Horses are Related to Differences in Behavioral Response to Frustration". Animals. 3 (3): 663–9. doi:10.3390/ani3030663. PMC 4494454. PMID 26479526.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  36. ^ Hori Y, Ozaki T, Yamada Y, Tozaki T, Kim HS, Takimoto A, Endo M, Manabe N, Inoue-Murayama M, Fujita K (2013). "Breed Differences in Dopamine Receptor D4 Gene (DRD4) in Horses". Journal of Equine Science. 24 (3): 31–6. doi:10.1294/jes.24.31. PMC 4013985. PMID 24833999.
  37. ^ Hejjas K, Vas J, Topal J, Szantai E, Ronai Z, Szekely A, Kubinyi E, Horvath Z, Sasvari-Szekely M, Miklosi A (December 2007). "Association of polymorphisms in the dopamine D4 receptor gene and the activity-impulsivity endophenotype in dogs". Animal Genetics. 38 (6): 629–33. doi:10.1111/j.1365-2052.2007.01657.x. PMID 17986156.
  38. ^ Timm, K.; Mägi, M.; Telva, K.; Tilgar, V. (2019). "The behavioural response of Great Tits to novel environment and handling is affected by the DRD4 gene". Ibis. 161 (2): 91–100. doi:10.1111/ibi.12604.
  39. ^ a b c d e Posner MI, Rothbart MK, Sheese BE, Voelker P (May 2012). "Control networks and neuromodulators of early development". Developmental Psychology. 48 (3): 827–35. doi:10.1037/a0025530. PMC 3253251. PMID 21942663.
  40. ^ Bernaerts P, Tirelli E (June 2003). "Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice". Behavioural Brain Research. 142 (1–2): 41–52. doi:10.1016/s0166-4328(02)00371-6. PMID 12798264.
  41. ^ Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, Brioni JD, Moreland RB, Fox GB (September 2005). "A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats". Pharmacology Biochemistry and Behavior. 82 (1): 148–55. doi:10.1016/j.pbb.2005.08.002. PMID 16154186.
  42. ^ Woolley ML, Waters KA, Reavill C, Bull S, Lacroix LP, Martyn AJ, Hutcheson DM, Valerio E, Bate S, Jones DN, Dawson LA (December 2008). "Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat". Behavioural Pharmacology. 19 (8): 765–76. doi:10.1097/FBP.0b013e32831c3b06. PMID 19020411.
  43. ^ Jentsch JD, Taylor JR, Redmond DE, Elsworth JD, Youngren KD, Roth RH (February 1999). "Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys". Psychopharmacology. 142 (1): 78–84. doi:10.1007/s002130050865. PMID 10102786.
  44. ^ Arnsten AF, Murphy B, Merchant K (October 2000). "The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys". Neuropsychopharmacology. 23 (4): 405–10. doi:10.1016/S0893-133X(00)00133-0. PMID 10989267.
  45. ^ Furth KE, McCoy AJ, Dodge C, Walters JR, Buonanno A, Delaville C (2017). "Neuronal correlates of ketamine and walking induced gamma oscillations in the medial prefrontal cortex and mediodorsal thalamus". PLOS ONE. 12 (11): e0186732. Bibcode:2017PLoSO..1286732F. doi:10.1371/journal.pone.0186732. PMC 5667758. PMID 29095852.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  46. ^ Kocsis B, Lee P, Deth R (November 2014). "Enhancement of gamma activity after selective activation of dopamine D4 receptors in freely moving rats and in a neurodevelopmental model of schizophrenia". Brain Structure & Function. 219 (6): 2173–80. doi:10.1007/s00429-013-0607-6. PMC 3859720. PMID 23839116.
  47. ^ Nakazawa S, Murai T, Miyauchi M, Kotani M, Ikeda K (September 2015). "Behavioral and neurophysiological effects of Ro 10-5824, a dopamine D4 receptor partial agonist, in common marmosets". Psychopharmacology. 232 (17): 3287–95. doi:10.1007/s00213-015-3978-y. PMID 26041337.
  48. ^ Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (October 2006). "WAY-100635 is a potent dopamine D4 receptor agonist". Psychopharmacology. 188 (2): 244–51. doi:10.1007/s00213-006-0490-4. PMID 16915381.
  49. ^ Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (September 2005). "A-412997 is a selective dopamine D4 receptor agonist in rats". Pharmacology Biochemistry and Behavior. 82 (1): 140–7. doi:10.1016/j.pbb.2005.08.001. PMID 16153699.
  50. ^ Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (July 2004). "Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction". Journal of Medicinal Chemistry. 47 (15): 3853–64. doi:10.1021/jm030505a. PMID 15239663.
  51. ^ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–65. doi:10.1021/jm060662k. PMID 17149874.
  52. ^ a b Hübner H, Kraxner J, Gmeiner P (November 2000). "Cyanoindole derivatives as highly selective dopamine D(4) receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments". Journal of Medicinal Chemistry. 43 (23): 4563–9. doi:10.1021/jm0009989. PMID 11087581.
  53. ^ Kolasa T, Matulenko MA, Hakeem AA, Patel MV, Mortell K, Bhatia P, Henry R, Nakane M, Hsieh GC, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino B, El Kouhen O, Marsh KC, Wetter JM, Moreland RB, Brioni JD, Stewart AO (August 2006). "1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (17): 5093–109. doi:10.1021/jm060279f. PMID 16913699.
  54. ^ Enguehard-Gueiffier C, Hübner H, El Hakmaoui A, Allouchi H, Gmeiner P, Argiolas A, Melis MR, Gueiffier A (June 2006). "2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist". Journal of Medicinal Chemistry. 49 (13): 3938–47. doi:10.1021/jm060166w. PMID 16789750.
  55. ^ Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB (July 2005). "2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist". Neuropharmacology. 49 (1): 112–21. doi:10.1016/j.neuropharm.2005.02.004. PMID 15992586.
  56. ^ a b Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P (March 2008). "Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: discovery of an inverse agonist radioligand for PET". Journal of Medicinal Chemistry. 51 (6): 1800–10. doi:10.1021/jm701375u. PMID 18307287.
  57. ^ Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, Emms F, Freedman SB, Marwood R, Patel S, Patel S, Ragan CI, Leeson PD (May 1996). "3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor". Journal of Medicinal Chemistry. 39 (10): 1941–2. doi:10.1021/jm9600712. PMID 8642550.
  58. ^ Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI (November 1997). "Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor". The Journal of Pharmacology and Experimental Therapeutics. 283 (2): 636–47. PMID 9353380.
  59. ^ Patel S, Patel S, Marwood R, Emms F, Marston D, Leeson PD, Curtis NR, Kulagowski JJ, Freedman SB (December 1996). "Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor". Molecular Pharmacology. 50 (6): 1658–64. PMID 8967990.
  60. ^ Berry CB, Bubser M, Jones CK, Hayes JP, Wepy JA, Locuson CW, Daniels JS, Lindsley CW, Hopkins CR (September 2014). "Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity". ACS Medicinal Chemistry Letters. 5 (9): 1060–4. doi:10.1021/ml500267c. PMC 4160761. PMID 25221667.
  61. ^ Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL (October 1998). "S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride". The Journal of Pharmacology and Experimental Therapeutics. 287 (1): 167–86. PMID 9765336.
  62. ^ Lanig H, Utz W, Gmeiner P (April 2001). "Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine". Journal of Medicinal Chemistry. 44 (8): 1151–7. doi:10.1021/jm001055e. PMID 11312915.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dopamine_receptor_D4&oldid=965312206"